These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 8545018)

  • 1. Immunization to reduce the frequency and severity of herpes zoster and its complications.
    Oxman MN
    Neurology; 1995 Dec; 45(12 Suppl 8):S41-6. PubMed ID: 8545018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine.
    Weinberg A; Zhang JH; Oxman MN; Johnson GR; Hayward AR; Caulfield MJ; Irwin MR; Clair J; Smith JG; Stanley H; Marchese RD; Harbecke R; Williams HM; Chan IS; Arbeit RD; Gershon AA; Schödel F; Morrison VA; Kauffman CA; Straus SE; Schmader KE; Davis LE; Levin MJ;
    J Infect Dis; 2009 Oct; 200(7):1068-77. PubMed ID: 19712037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial.
    Trannoy E; Berger R; Holländer G; Bailleux F; Heimendinger P; Vuillier D; Creusvaux H
    Vaccine; 2000 Feb; 18(16):1700-6. PubMed ID: 10689152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Possibility of prevention of herpes zoster by use of varicella vaccine].
    Kawano S; Terada K; Yagi Y; Kataoka N
    Kansenshogaku Zasshi; 1998 Jul; 72(7):714-9. PubMed ID: 9745221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine.
    Levin MJ; Oxman MN; Zhang JH; Johnson GR; Stanley H; Hayward AR; Caulfield MJ; Irwin MR; Smith JG; Clair J; Chan IS; Williams H; Harbecke R; Marchese R; Straus SE; Gershon A; Weinberg A;
    J Infect Dis; 2008 Mar; 197(6):825-35. PubMed ID: 18419349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An inverse correlation of VZV skin-test reaction, but not antibody, with severity of herpes zoster skin symptoms and zoster-associated pain.
    Asada H; Nagayama K; Okazaki A; Mori Y; Okuno Y; Takao Y; Miyazaki Y; Onishi F; Okeda M; Yano S; Kumihashi H; Gomi Y; Maeda K; Ishikawa T; Iso H; Yamanishi K;
    J Dermatol Sci; 2013 Mar; 69(3):243-9. PubMed ID: 23183011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Varicella zoster virus-specific immune responses to a herpes zoster vaccine in elderly recipients with major depression and the impact of antidepressant medications.
    Irwin MR; Levin MJ; Laudenslager ML; Olmstead R; Lucko A; Lang N; Carrillo C; Stanley HA; Caulfield MJ; Weinberg A; Chan IS; Clair J; Smith JG; Marchese RD; Williams HM; Beck DJ; McCook PT; Zhang JH; Johnson G; Oxman MN
    Clin Infect Dis; 2013 Apr; 56(8):1085-93. PubMed ID: 23413415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Varicella-zoster virus-specific cell-mediated immunity by interferon-γ Enzyme-Linked Immunosorbent Assay in adults ≥50 years of age administered a herpes zoster vaccine.
    Yang P; Chen Z; Zhang J; Li W; Zhu C; Qiu P; Quan Y; Cui X; Yuan L; Jiang C
    J Med Virol; 2019 May; 91(5):829-835. PubMed ID: 30613990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VZV-specific cell-mediated immunity, but not humoral immunity, correlates inversely with the incidence of herpes zoster and the severity of skin symptoms and zoster-associated pain: The SHEZ study.
    Asada H
    Vaccine; 2019 Oct; 37(44):6776-6781. PubMed ID: 31543415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular and Humoral Responses to a Second Dose of Herpes Zoster Vaccine Administered 10 Years After the First Dose Among Older Adults.
    Levin MJ; Schmader KE; Pang L; Williams-Diaz A; Zerbe G; Canniff J; Johnson MJ; Caldas Y; Cho A; Lang N; Su SC; Parrino J; Popmihajlov Z; Weinberg A
    J Infect Dis; 2016 Jan; 213(1):14-22. PubMed ID: 26452397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine.
    Levin MJ; Smith JG; Kaufhold RM; Barber D; Hayward AR; Chan CY; Chan IS; Li DJ; Wang W; Keller PM; Shaw A; Silber JL; Schlienger K; Chalikonda I; Vessey SJ; Caulfield MJ
    J Infect Dis; 2003 Nov; 188(9):1336-44. PubMed ID: 14593591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restoration of varicella-zoster virus cell-mediated immune response after varicella booster vaccination.
    Berger R; Luescher D; Just M
    Postgrad Med J; 1985; 61 Suppl 4():143-5. PubMed ID: 3014472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune senescence and vaccines to prevent herpes zoster in older persons.
    Levin MJ
    Curr Opin Immunol; 2012 Aug; 24(4):494-500. PubMed ID: 22857823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient induction of cell-mediated immunity to varicella-zoster virus glycoprotein E co-lyophilized with a cationic liposome-based adjuvant in mice.
    Wui SR; Kim KS; Ryu JI; Ko A; Do HTT; Lee YJ; Kim HJ; Lim SJ; Park SA; Cho YJ; Kim CG; Lee NG
    Vaccine; 2019 Apr; 37(15):2131-2141. PubMed ID: 30827737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling the impact of combined vaccination programs against varicella and herpes zoster in Norway.
    Marchetti S; Guzzetta G; Flem E; Mirinaviciute G; Scalia Tomba G; Manfredi P
    Vaccine; 2018 Feb; 36(8):1116-1125. PubMed ID: 29366704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perspectives on vaccines against varicella-zoster virus infections.
    Gershon AA; Gershon MD
    Curr Top Microbiol Immunol; 2010; 342():359-72. PubMed ID: 20232192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Herpes zoster pathogenesis and cell-mediated immunity and immunosenescence.
    Oxman MN
    J Am Osteopath Assoc; 2009 Jun; 109(6 Suppl 2):S13-7. PubMed ID: 19553630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between cell-mediated immunity to Varicella-Zoster virus and aging in subjects from the community-based Shozu Herpes Zoster study.
    Shirane R; Tang H; Hayashi K; Okuno Y; Iso H; Asada H; Yamanishi K; Mori Y;
    J Med Virol; 2017 Feb; 89(2):313-317. PubMed ID: 27420414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrent herpes zoster in the Shingles Prevention Study: Are second episodes caused by the same varicella-zoster virus strain?
    Harbecke R; Jensen NJ; Depledge DP; Johnson GR; Ashbaugh ME; Schmid DS; Breuer J; Levin MJ; Oxman MN
    Vaccine; 2020 Jan; 38(2):150-157. PubMed ID: 31679866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel vaccine (Zostavax) to prevent herpes zoster and postherpetic neuralgia.
    Holcomb K; Weinberg JM
    J Drugs Dermatol; 2006 Oct; 5(9):863-6. PubMed ID: 17039651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.